Daxor announces a review published in the journal Cardiorenal Medicine that delves into the intricate landscape of cardiorenal syndrome, CRS, and highlights the pivotal role of Blood Volume Analysis, BVA, in improving patient care and outcomes. Key findings: BVA as a diagnostic tool enhances the precision of diuretic and red cell therapies, significantly elevating the effectiveness of conventional care. Integrating BVA in CRS care has clinical implications, including personalized treatment and improved outcomes. The heart-kidney relationship in CRS underscores the need for precise, personalized care, where BVA plays a crucial role.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXR:
- Daxor receives $300K matching fund award from Launch Tennessee
- Central Florida hospital implements Daxor BVA-100 blood volume diagnostic
- Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
- Daxor CEO says NAV increased to $6.75 p/s from $6.33 last year this time
- Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference